vs
ASP Isotopes Inc.（ASPI）与Fortress Biotech, Inc.（FBIO）财务数据对比。点击上方公司名可切换其他公司
ASP Isotopes Inc.的季度营收约是Fortress Biotech, Inc.的1.0倍（$16.7M vs $16.1M），ASP Isotopes Inc.同比增速更快（1295.7% vs 6.3%）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
堡垒生物科技（Fortress Biotech）是一家生物制药企业，核心业务为收购、开发并商业化创新医药与生物技术产品。公司由医学博士林赛·A·罗森瓦尔德担任首席执行官，包括绝大多数子公司在内，公司总部均设于佛罗里达州贝港群岛。
ASPI vs FBIO — 直观对比
营收规模更大
ASPI
是对方的1.0倍
$16.1M
营收增速更快
ASPI
高出1289.4%
6.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $16.1M |
| 净利润 | — | $-3.9M |
| 毛利率 | 12.5% | 66.1% |
| 营业利润率 | — | -28.8% |
| 净利率 | — | -24.5% |
| 营收同比 | 1295.7% | 6.3% |
| 净利润同比 | -586.8% | 41.8% |
| 每股收益（稀释后） | — | $-0.15 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPIFBIO
| Q4 25 | $16.7M | $16.1M | ||
| Q3 25 | $4.9M | $17.6M | ||
| Q2 25 | — | $16.4M | ||
| Q1 25 | — | $13.1M | ||
| Q4 24 | — | $15.1M | ||
| Q3 24 | — | $14.6M | ||
| Q2 24 | — | $14.9M | ||
| Q1 24 | — | $13.0M |
净利润ASPIFBIO
| Q4 25 | — | $-3.9M | ||
| Q3 25 | $-12.9M | $5.8M | ||
| Q2 25 | — | $15.5M | ||
| Q1 25 | — | $-10.6M | ||
| Q4 24 | — | $-6.8M | ||
| Q3 24 | — | $-12.9M | ||
| Q2 24 | — | $-10.9M | ||
| Q1 24 | — | $-15.4M |
毛利率ASPIFBIO
| Q4 25 | 12.5% | 66.1% | ||
| Q3 25 | 8.7% | 67.4% | ||
| Q2 25 | — | 69.9% | ||
| Q1 25 | — | 63.5% | ||
| Q4 24 | — | 69.1% | ||
| Q3 24 | — | 69.4% | ||
| Q2 24 | — | 61.6% | ||
| Q1 24 | — | 53.9% |
营业利润率ASPIFBIO
| Q4 25 | — | -28.8% | ||
| Q3 25 | -306.1% | -38.6% | ||
| Q2 25 | — | -222.2% | ||
| Q1 25 | — | -169.9% | ||
| Q4 24 | — | -158.3% | ||
| Q3 24 | — | -151.0% | ||
| Q2 24 | — | -186.5% | ||
| Q1 24 | — | -280.6% |
净利率ASPIFBIO
| Q4 25 | — | -24.5% | ||
| Q3 25 | -263.7% | 33.2% | ||
| Q2 25 | — | 94.4% | ||
| Q1 25 | — | -80.6% | ||
| Q4 24 | — | -44.7% | ||
| Q3 24 | — | -88.0% | ||
| Q2 24 | — | -73.5% | ||
| Q1 24 | — | -118.3% |
每股收益（稀释后）ASPIFBIO
| Q4 25 | — | $-0.15 | ||
| Q3 25 | $-0.15 | $0.11 | ||
| Q2 25 | — | $0.45 | ||
| Q1 25 | — | $-0.48 | ||
| Q4 24 | — | $-0.16 | ||
| Q3 24 | — | $-0.76 | ||
| Q2 24 | — | $-0.73 | ||
| Q1 24 | — | $-1.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $79.4M |
| 总债务越低越好 | $14.4M | $52.4M |
| 股东权益账面价值 | $204.2M | $49.9M |
| 总资产 | $498.0M | $185.5M |
| 负债/权益比越低杠杆越低 | 0.07× | 1.05× |
8季度趋势，按日历期对齐
现金及短期投资ASPIFBIO
| Q4 25 | $333.3M | $79.4M | ||
| Q3 25 | $113.9M | $86.2M | ||
| Q2 25 | — | $74.4M | ||
| Q1 25 | — | $91.3M | ||
| Q4 24 | — | $57.3M | ||
| Q3 24 | — | $58.9M | ||
| Q2 24 | — | $76.2M | ||
| Q1 24 | — | $83.8M |
总债务ASPIFBIO
| Q4 25 | $14.4M | $52.4M | ||
| Q3 25 | $13.9M | $47.8M | ||
| Q2 25 | — | $50.0M | ||
| Q1 25 | — | $56.4M | ||
| Q4 24 | — | $58.0M | ||
| Q3 24 | — | $52.5M | ||
| Q2 24 | — | $67.0M | ||
| Q1 24 | — | $61.4M |
股东权益ASPIFBIO
| Q4 25 | $204.2M | $49.9M | ||
| Q3 25 | $74.1M | $55.9M | ||
| Q2 25 | — | $43.9M | ||
| Q1 25 | — | $22.3M | ||
| Q4 24 | — | $22.7M | ||
| Q3 24 | — | $21.2M | ||
| Q2 24 | — | $17.9M | ||
| Q1 24 | — | $23.0M |
总资产ASPIFBIO
| Q4 25 | $498.0M | $185.5M | ||
| Q3 25 | $225.9M | $181.4M | ||
| Q2 25 | — | $159.9M | ||
| Q1 25 | — | $178.1M | ||
| Q4 24 | — | $144.2M | ||
| Q3 24 | — | $127.1M | ||
| Q2 24 | — | $145.7M | ||
| Q1 24 | — | $164.6M |
负债/权益比ASPIFBIO
| Q4 25 | 0.07× | 1.05× | ||
| Q3 25 | 0.19× | 0.86× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | 2.53× | ||
| Q4 24 | — | 2.55× | ||
| Q3 24 | — | 2.48× | ||
| Q2 24 | — | 3.75× | ||
| Q1 24 | — | 2.67× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-12.5M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | — |
| 自由现金流率自由现金流/营收 | -284.7% | — |
| 资本支出强度资本支出/营收 | 57.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASPIFBIO
| Q4 25 | $-37.8M | $-12.5M | ||
| Q3 25 | $-8.9M | $-6.1M | ||
| Q2 25 | — | $-27.6M | ||
| Q1 25 | — | $-19.6M | ||
| Q4 24 | — | $-12.9M | ||
| Q3 24 | — | $-20.1M | ||
| Q2 24 | — | $-21.8M | ||
| Q1 24 | — | $-25.4M |
自由现金流ASPIFBIO
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率ASPIFBIO
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度ASPIFBIO
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率ASPIFBIO
| Q4 25 | — | — | ||
| Q3 25 | — | -1.04× | ||
| Q2 25 | — | -1.78× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
